Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Phase of Trial: Phase I/II
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 09 Apr 2017 Planned End Date changed from 1 Jan 2017 to 31 Jan 2019.
- 09 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Jan 2019.
- 29 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.